Sign In
Buy CPRX
$31.28
+0.0100 (+0.0320%)
At Close: Jun 03, 2026
Catalyst Pharmaceuticals: Undervalued Future With Multiple Upside Catalysts
04:05am, Tuesday, 11'th Mar 2025
Catalyst Pharmaceuticals' current stock price only assumes historical momentum for existing drug portfolio continues, undervaluing future upside potentials. CPRX stock's upside potential is driven by
Catalyst Pharmaceuticals to Participate in the Barclays 27th Annual Global Healthcare Conference
08:03am, Tuesday, 04'th Mar 2025
CORAL GABLES, Fla., March 04, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, de
Catalyst Pharmaceuticals: Stable Firdapse, Promising Agamree, Fycompa Challenges
02:39pm, Monday, 03'rd Mar 2025
Firdapse drives Catalyst Pharmaceuticals, Inc.'s revenue with a 37% CAGR since its 2019 launch, boosted by an FDA-approved 100 mg dose expansion. Agamree targets DMD and has so far generated $46 m
Here's What's Driving Catalyst Pharmaceuticals Stock 8% Higher Today
02:35pm, Thursday, 27'th Feb 2025
Shares of drugmaker Catalyst Pharmaceuticals (CPRX 5.54%) are up a little more than 8% as of midday on Thursday, down slightly from an intraday peak gain of nearly 13%. The company's fourth-quarter re
Catalyst Pharmaceuticals, Inc. (CPRX) Q4 2024 Earnings Call Transcript
12:29pm, Thursday, 27'th Feb 2025
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX ) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Michael Kalb - Executive Vice President & Chief Financial Officer Richa
CPRX Q4 Earnings Beat, Firdapse Sales Boost Revenues, Stock Up
10:10am, Thursday, 27'th Feb 2025
Catalyst stock gains on strong fourth-quarter results, beating earnings and revenue estimates, primarily driven by Firdapse sales.
Catalyst (CPRX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
09:30pm, Wednesday, 26'th Feb 2025
The headline numbers for Catalyst (CPRX) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street esti
Catalyst Pharmaceutical (CPRX) Tops Q4 Earnings and Revenue Estimates
07:50pm, Wednesday, 26'th Feb 2025
Catalyst Pharmaceutical (CPRX) came out with quarterly earnings of $0.70 per share, beating the Zacks Consensus Estimate of $0.52 per share. This compares to earnings of $0.53 per share a year ago.
Catalyst Pharmaceuticals Reports Record Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
04:13pm, Wednesday, 26'th Feb 2025
Full Year 2024 Total Revenues of $491.7 Million, Marking Another Year of Record Growth Full Year 2024 Total Revenues Grew 23.5% YoY, Driven by Strong Commercial Performance Q4 2024 Net Product Revenue
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2024 Financial Results on February 26, 2025
08:03am, Wednesday, 12'th Feb 2025
CORAL GABLES, Fla., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, de
Catalyst Remains a Big Money Favorite
03:56pm, Friday, 07'th Feb 2025
Catalyst Pharmaceuticals, Inc. (CPRX) shares keep gaining on Big Money buys.
This Drug Stock Sits On A Strong Earnings Foundation As It Tests New Entry
08:00am, Friday, 31'st Jan 2025
This pharma stock has made strong gains over the past 12 months thanks to its strong earnings. Now it is testing a fresh buy point.
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Momentum Stock
10:55am, Friday, 24'th Jan 2025
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2025 List of America's Most Successful Mid-Cap Companies
08:03am, Thursday, 23'rd Jan 2025
CORAL GABLES, Fla., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today announced its inclusion in Forbes' esteemed list of America's Most S
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
09:55am, Wednesday, 22'nd Jan 2025
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
